REZOLUTE, INC. Research and Development Expense
REZOLUTE, INC. (RZLT) reported Research and Development Expense of $53.80 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-24
- REZOLUTE, INC. research and development expense for the quarter ending 2026-06-30 was $14.89M, a 28.63% decline year-over-year.
- REZOLUTE, INC. research and development expense for the quarter ending 2026-03-31 was $11.41M, a 25.33% decline year-over-year.
- REZOLUTE, INC. research and development expense for the quarter ending 2025-12-31 was $14.35M, a 13.63% increase year-over-year.
- REZOLUTE, INC. research and development expense for the quarter ending 2025-09-30 was $13.15M, a 3.10% increase year-over-year.
- REZOLUTE, INC. research and development expense for fiscal 2026 was $53.80M, a 12.56% decline from fiscal 2025.
- REZOLUTE, INC. research and development expense for fiscal 2025 was $61.53M, a 10.38% increase from fiscal 2024.
- REZOLUTE, INC. research and development expense for fiscal 2024 was $55.74M, a 27.23% increase from fiscal 2023.
- REZOLUTE, INC. research and development expense for fiscal 2023 was $43.81M, a 34.87% increase from fiscal 2022.
| Period end | Research and Development Expense 2 month | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 5 month | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 8 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 11 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 14 month | Research and Development Expense 17 month | Research and Development Expense 20 month | Research and Development Expense 26 month | Research and Development Expense 29 month | Research and Development Expense 36 month | Research and Development Expense 39 month | Research and Development Expense 42 month | Research and Development Expense 45 month | Research and Development Expense 48 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-24 | $26.30M derived: sum of 2 quarters · filed 2026-09-24 | $40.65M derived: sum of 3 quarters · filed 2026-09-24 | $53.80M 10-K · filed 2026-09-24 | ||||||||||||||||||
| 2026-03-31 | $11.41M 10-Q · filed 2026-05-12 | $25.76M derived: sum of 2 quarters · filed 2026-05-12 | $38.91M 10-Q · filed 2026-05-12 | $59.77M derived: sum of 4 quarters · filed 2026-09-24 | ||||||||||||||||||
| 2025-12-31 | $14.35M 10-Q · filed 2026-02-12 | $27.50M 10-Q · filed 2026-02-12 | $48.36M derived: sum of 3 quarters · filed 2026-09-24 | $63.64M derived: sum of 4 quarters · filed 2026-09-24 | ||||||||||||||||||
| 2025-09-30 | $13.15M 10-Q · filed 2025-11-06 | $34.01M derived: sum of 2 quarters · filed 2026-09-24 | $49.30M derived: sum of 3 quarters · filed 2026-09-24 | $61.92M derived: sum of 4 quarters · filed 2026-09-24 | ||||||||||||||||||
| 2025-06-30 | $20.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-24 | $36.15M derived: sum of 2 quarters · filed 2026-09-24 | $48.77M derived: sum of 3 quarters · filed 2026-09-24 | $61.53M 10-K · filed 2026-09-24 | ||||||||||||||||||
| 2025-03-31 | $15.28M 10-Q · filed 2026-05-12 | $27.91M derived: sum of 2 quarters · filed 2026-05-12 | $40.66M 10-Q · filed 2026-05-12 | $59.75M derived: sum of 4 quarters · filed 2026-05-12 | ||||||||||||||||||
| 2024-12-31 | $12.63M 10-Q · filed 2026-02-12 | $25.38M 10-Q · filed 2026-02-12 | $44.47M derived: sum of 3 quarters · filed 2026-02-12 | $56.87M derived: sum of 4 quarters · filed 2026-02-12 | ||||||||||||||||||
| 2024-09-30 | $12.75M 10-Q · filed 2025-11-06 | $31.84M derived: sum of 2 quarters · filed 2025-11-06 | $44.24M derived: sum of 3 quarters · filed 2025-11-06 | $56.28M derived: sum of 4 quarters · filed 2025-11-06 | ||||||||||||||||||
| 2024-06-30 | $19.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-17 | $31.49M derived: sum of 2 quarters · filed 2025-09-17 | $43.53M derived: sum of 3 quarters · filed 2025-09-17 | $55.74M 10-K · filed 2025-09-17 | ||||||||||||||||||
| 2024-03-31 | $12.40M 10-Q · filed 2025-05-13 | $24.44M derived: sum of 2 quarters · filed 2025-05-13 | $36.65M 10-Q · filed 2025-05-13 | $47.59M derived: sum of 4 quarters · filed 2025-05-13 | ||||||||||||||||||
| 2023-12-31 | $12.04M 10-Q · filed 2025-02-12 | $24.25M 10-Q · filed 2025-02-12 | $35.19M derived: sum of 3 quarters · filed 2025-02-12 | $49.42M derived: sum of 4 quarters · filed 2025-02-12 | ||||||||||||||||||
| 2023-09-30 | $12.21M 10-Q · filed 2024-11-07 | $23.15M derived: sum of 2 quarters · filed 2024-11-07 | $37.38M derived: sum of 3 quarters · filed 2024-11-07 | $48.32M derived: sum of 4 quarters · filed 2024-11-07 | ||||||||||||||||||
| 2023-06-30 | $10.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-19 | $25.16M derived: sum of 2 quarters · filed 2024-09-19 | $36.11M derived: sum of 3 quarters · filed 2024-09-19 | $43.81M 10-K · filed 2024-09-19 | ||||||||||||||||||
| 2023-03-31 | $14.23M 10-Q · filed 2024-05-15 | $25.18M derived: sum of 2 quarters · filed 2024-05-15 | $32.88M 10-Q · filed 2024-05-15 | $41.45M derived: sum of 4 quarters · filed 2024-05-15 | ||||||||||||||||||
| 2022-12-31 | $10.95M 10-Q · filed 2024-02-13 | $18.65M 10-Q · filed 2024-02-13 | $27.22M derived: sum of 3 quarters · filed 2024-02-13 | $35.91M derived: sum of 4 quarters · filed 2024-02-13 | ||||||||||||||||||
| 2022-09-30 | $7.70M 10-Q · filed 2023-11-13 | $16.28M derived: sum of 2 quarters · filed 2023-11-13 | $24.96M derived: sum of 3 quarters · filed 2023-11-13 | $34.42M derived: sum of 4 quarters · filed 2023-11-13 | ||||||||||||||||||
| 2022-06-30 | $8.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-14 | $17.26M derived: sum of 2 quarters · filed 2023-09-14 | $26.71M derived: sum of 3 quarters · filed 2023-09-14 | $32.49M 10-K · filed 2023-09-14 | ||||||||||||||||||
| 2022-03-31 | $8.69M 10-Q · filed 2023-05-11 | $18.14M derived: sum of 2 quarters · filed 2023-05-11 | $23.91M 10-Q · filed 2023-05-11 | $28.30M derived: sum of 4 quarters · filed 2023-05-11 | ||||||||||||||||||
| 2021-12-31 | $9.45M 10-Q · filed 2023-02-10 | $15.23M 10-Q · filed 2023-02-10 | $19.61M derived: sum of 3 quarters · filed 2023-02-10 | $23.37M derived: sum of 4 quarters · filed 2023-02-10 | ||||||||||||||||||
| 2021-09-30 | $5.77M 10-Q · filed 2022-11-09 | $10.16M derived: sum of 2 quarters · filed 2022-11-09 | $13.92M derived: sum of 3 quarters · filed 2022-11-09 | $18.42M derived: sum of 4 quarters · filed 2022-11-09 | ||||||||||||||||||
| 2021-06-30 | $4.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-15 | $8.15M derived: sum of 2 quarters · filed 2022-09-15 | $12.64M derived: sum of 3 quarters · filed 2022-09-15 | $14.99M 10-K · filed 2022-09-15 | ||||||||||||||||||
| 2021-03-31 | $3.76M 10-Q · filed 2022-05-12 | $8.25M derived: sum of 2 quarters · filed 2022-05-12 | $10.60M 10-Q · filed 2022-05-12 | $13.04M derived: sum of 4 quarters · filed 2022-05-12 | ||||||||||||||||||
| 2020-12-31 | $4.50M 10-Q · filed 2022-02-09 | $6.84M 10-Q · filed 2022-02-09 | $9.29M derived: sum of 3 quarters · filed 2022-02-09 | $13.02M derived: sum of 4 quarters · filed 2022-02-09 | ||||||||||||||||||
| 2020-09-30 | $2.34M 10-Q · filed 2021-11-12 | $4.79M derived: sum of 2 quarters · filed 2021-11-12 | $8.52M derived: sum of 3 quarters · filed 2021-11-12 | $13.56M derived: sum of 4 quarters · filed 2021-11-12 | ||||||||||||||||||
| 2020-06-30 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-15 | $6.18M derived: sum of 2 quarters · filed 2021-09-15 | $11.22M derived: sum of 3 quarters · filed 2021-09-15 | $14.45M 10-K · filed 2021-09-15 | ||||||||||||||||||
| 2020-03-31 | $3.73M 10-Q · filed 2021-05-17 | $8.77M derived: sum of 2 quarters · filed 2021-05-17 | $12.01M 10-Q · filed 2021-05-17 | $13.72M derived: sum of 4 quarters · filed 2021-05-17 | ||||||||||||||||||
| 2019-12-31 | $5.04M 10-Q · filed 2021-02-10 | $8.27M 10-Q · filed 2021-02-10 | $9.99M derived: sum of 3 quarters · filed 2021-02-10 | $25.11M derived: sum of 4 quarters · filed 2021-02-10 | ||||||||||||||||||
| 2019-09-30 | $3.23M 10-Q · filed 2020-11-12 | $4.95M derived: sum of 2 quarters · filed 2020-11-12 | $20.07M derived: sum of 3 quarters · filed 2020-11-12 | $21.38M derived: sum of 4 quarters · filed 2020-11-12 | ||||||||||||||||||
| 2019-06-30 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-13 | $16.84M derived: sum of 2 quarters · filed 2020-10-13 | $18.15M derived: sum of 3 quarters · filed 2020-10-13 | $19.08M 10-K · filed 2020-10-13 | ||||||||||||||||||
| 2019-03-31 | $15.12M 10-Q · filed 2020-05-14 | $15.12M 10-Q · filed 2019-05-10 | $16.43M derived: sum of 2 quarters · filed 2020-05-14 | $17.36M 10-Q · filed 2020-05-14 | $17.36M 10-Q · filed 2019-05-10 | $24.42M derived: sum of 4 quarters · filed 2020-05-14 | ||||||||||||||||
| 2018-12-31 | $1.31M 10-Q · filed 2020-02-12 | $1.31M 10-Q · filed 2019-02-14 | $2.24M 10-Q · filed 2020-02-12 | $2.24M 10-Q · filed 2019-02-14 | $9.30M derived: sum of 3 quarters · filed 2020-02-12 | $11.80M derived: sum of 4 quarters · filed 2020-02-12 | ||||||||||||||||
| 2018-09-30 | $930.00K 10-Q · filed 2019-11-14 | $929.91K 10-Q · filed 2018-12-14 | $7.99M derived: sum of 2 quarters · filed 2019-11-14 | $10.49M derived: sum of 3 quarters · filed 2019-11-14 | $13.90M derived: sum of 4 quarters · filed 2019-11-14 | |||||||||||||||||
| 2018-06-30 | $7.06M derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-10 | $9.56M derived: sum of 2 quarters · filed 2019-09-10 | $12.97M derived: sum of 3 quarters · filed 2019-09-10 | $17.28M 10-K · filed 2019-09-10 | $17.28M 10-K · filed 2018-10-15 | |||||||||||||||||
| 2018-03-31 | $2.50M 10-Q · filed 2019-05-10 | $5.91M derived: sum of 2 quarters · filed 2019-05-10 | $10.22M 10-Q · filed 2019-05-10 | $13.31M derived: sum of 4 quarters · filed 2019-05-10 | ||||||||||||||||||
| 2017-12-31 | $3.41M 10-Q · filed 2019-02-14 | $7.72M 10-Q · filed 2019-02-14 | $10.82M derived: sum of 3 quarters · filed 2019-02-14 | $14.26M derived: sum of 4 quarters · filed 2019-02-14 | ||||||||||||||||||
| 2017-09-30 | $4.31M 10-Q · filed 2018-12-14 | $7.40M derived: sum of 2 quarters · filed 2018-12-14 | $10.84M derived: sum of 3 quarters · filed 2018-12-14 | $13.92M derived: sum of 4 quarters · filed 2018-12-14 | ||||||||||||||||||
| 2017-06-30 | $3.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-15 | $6.53M derived: sum of 2 quarters · filed 2018-10-15 | $9.61M derived: sum of 3 quarters · filed 2018-10-15 | $12.09M 10-K · filed 2018-10-15 | ||||||||||||||||||
| 2017-03-31 | $3.44M 10-Q · filed 2018-05-15 | $6.51M derived: sum of 2 quarters · filed 2018-05-15 | $9.00M 10-Q · filed 2018-05-15 | $11.65M derived: sum of 4 quarters · filed 2018-05-15 | ||||||||||||||||||
| 2016-12-31 | $3.08M 10-Q · filed 2018-02-14 | $5.56M 10-Q · filed 2018-02-14 | $8.21M derived: sum of 3 quarters · filed 2018-02-14 | $10.52M derived: sum of 4 quarters · filed 2018-02-14 | ||||||||||||||||||
| 2016-09-30 | $2.49M 10-Q · filed 2017-11-14 | $5.13M derived: sum of 2 quarters · filed 2017-11-14 | $7.44M derived: sum of 3 quarters · filed 2017-11-14 | $9.97M derived: sum of 4 quarters · filed 2017-11-14 | ||||||||||||||||||
| 2016-06-30 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-22 | $4.96M derived: sum of 2 quarters · filed 2017-09-22 | $7.48M derived: sum of 3 quarters · filed 2017-09-22 | $9.45M 10-K · filed 2017-09-22 | ||||||||||||||||||
| 2016-03-31 | $2.31M 10-Q · filed 2017-05-15 | $4.83M derived: sum of 2 quarters · filed 2017-05-15 | $6.80M 10-Q · filed 2017-05-15 | $8.53M derived: sum of 4 quarters · filed 2017-05-15 | ||||||||||||||||||
| 2015-12-31 | $2.52M 10-Q · filed 2017-02-02 | $4.49M 10-Q · filed 2017-02-02 | $6.22M derived: sum of 3 quarters · filed 2017-02-02 | $7.51M derived: sum of 4 quarters · filed 2017-02-02 | ||||||||||||||||||
| 2015-09-30 | $1.97M 10-Q · filed 2016-11-14 | $3.70M derived: sum of 2 quarters · filed 2016-11-14 | $4.99M derived: sum of 3 quarters · filed 2016-11-14 | $6.56M derived: sum of 4 quarters · filed 2016-11-14 | ||||||||||||||||||
| 2015-06-30 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-28 | $3.02M derived: sum of 2 quarters · filed 2016-09-28 | $4.59M derived: sum of 3 quarters · filed 2016-09-28 | $4.70M 10-K · filed 2016-09-28 | ||||||||||||||||||
| 2015-03-31 | $1.29M 10-Q · filed 2016-05-16 | $2.86M derived: sum of 2 quarters · filed 2016-05-16 | $2.97M 10-Q · filed 2016-05-16 | $3.00M derived: sum of 4 quarters · filed 2016-05-16 | ||||||||||||||||||
| 2014-12-31 | $1.57M 10-Q · filed 2016-02-16 | $1.68M 10-Q · filed 2016-02-16 | $1.71M derived: sum of 3 quarters · filed 2016-02-16 | $1.71M derived: sum of 4 quarters · filed 2016-02-16 | ||||||||||||||||||
| 2014-09-30 | $112.56K 10-Q · filed 2015-11-16 | $144.63K derived: sum of 2 quarters · filed 2015-11-16 | $146.88K derived: sum of 3 quarters · filed 2015-11-16 | $146.88K derived: sum of 4 quarters · filed 2015-11-16 | ||||||||||||||||||
| 2014-06-30 | $32.07K derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-28 | $34.32K derived: sum of 2 quarters · filed 2015-09-28 | $34.32K derived: sum of 3 quarters · filed 2015-09-28 | $34.32K 10-K · filed 2015-09-28 | ||||||||||||||||||
| 2014-03-31 | $2.25K 10-Q · filed 2015-05-15 | $2.25K derived: sum of 2 quarters · filed 2015-05-15 | $2.25K 10-Q · filed 2015-05-15 | $2.71K derived: sum of 4 quarters · filed 2015-05-15 | $5.74K 10-Q · filed 2014-05-14 | |||||||||||||||||
| 2013-12-31 | $0.00 10-Q · filed 2015-02-17 | $0.00 10-Q · filed 2015-02-17 | $469.00 derived: sum of 3 quarters · filed 2015-02-17 | $3.49K derived: sum of 4 quarters · filed 2015-02-17 | $3.49K 10-Q · filed 2014-02-13 | |||||||||||||||||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-12 | $469.00 derived: sum of 2 quarters · filed 2014-11-12 | $3.49K derived: sum of 3 quarters · filed 2014-11-12 | $3.49K derived: sum of 4 quarters · filed 2014-11-12 | $3.49K 10-Q · filed 2013-11-12 | |||||||||||||||||
| 2013-06-30 | $469.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-30 | $3.49K derived: sum of 2 quarters · filed 2014-09-30 | $3.49K derived: sum of 3 quarters · filed 2014-09-30 | $3.49K 10-K · filed 2014-09-30 | $3.49K 10-K · filed 2013-09-11 | |||||||||||||||||
| 2013-03-31 | $3.02K 10-Q · filed 2014-05-14 | $3.02K derived: sum of 2 quarters · filed 2014-05-14 | $3.02K 10-Q · filed 2014-05-14 | $3.02K derived: sum of 4 quarters · filed 2014-05-14 | $3.02K 10-Q · filed 2013-05-15 | |||||||||||||||||
| 2012-12-31 | $0.00 10-Q · filed 2014-02-13 | $0.00 10-Q · filed 2014-02-13 | $0.00 derived: sum of 3 quarters · filed 2014-02-13 | $0.00 derived: sum of 4 quarters · filed 2014-02-13 | $24.50K 10-Q · filed 2013-02-14 | |||||||||||||||||
| 2012-09-30 | $0.00 10-Q · filed 2013-11-12 | $0.00 derived: sum of 2 quarters · filed 2013-11-12 | $0.00 derived: sum of 3 quarters · filed 2013-11-12 | $24.50K 10-Q · filed 2012-11-19 | ||||||||||||||||||
| 2012-06-30 | $0.00 derived: 10-K 6 month − 10-Q 3 month · filed 2013-09-11 | $0.00 10-K · filed 2013-09-11 | $24.50K 10-K/A · filed 2012-11-09 | $0.00 10-K/A · filed 2012-11-09 | ||||||||||||||||||
| 2012-03-31 | $0.00 10-Q · filed 2013-05-15 | $0.00 10-Q · filed 2013-05-15 | $24.50K 10-Q · filed 2012-05-15 | |||||||||||||||||||
| 2011-12-31 | $0.00 10-K · filed 2013-09-11 | $24.50K 10-Q · filed 2012-02-14 | ||||||||||||||||||||
| 2011-09-30 | $24.50K 10-Q/A · filed 2011-12-13 | |||||||||||||||||||||
| 2011-06-30 | $24.50K 10-K/A · filed 2012-11-09 | |||||||||||||||||||||
| 2011-03-31 | $23.92K 10-Q · filed 2012-05-15 | $24.50K 10-Q · filed 2012-05-15 | ||||||||||||||||||||
| 2010-12-31 | $24.50K 10-Q · filed 2012-02-14 | |||||||||||||||||||||
| 2010-09-30 | $24.50K 10-Q/A · filed 2011-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |